Φορτώνει......

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutic drugs have become mainstream cancer treatments. Since the first tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration (FDA) in 2001, an...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Signal Transduct Target Ther
Κύριοι συγγραφείς: Zhong, Lei, Li, Yueshan, Xiong, Liang, Wang, Wenjing, Wu, Ming, Yuan, Ting, Yang, Wei, Tian, Chenyu, Miao, Zhuang, Wang, Tianqi, Yang, Shengyong
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Nature Publishing Group UK 2021
Θέματα:
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8165101/
https://ncbi.nlm.nih.gov/pubmed/34054126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41392-021-00572-w
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!